Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...
ReMEDy1 Data Informing Current Stroke Trial -- In moderate stroke patients (NIHSS 5-15), a 19% absolute functional outcome ...
THE 52ND ANNUAL Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in the highest-altitude ...
Zacks Small Cap Research on MSN
CVKD: Designing phase 3 trial for CAD-1005 in HIT
By David Bautz, PhD NASDAQ: CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Planning for Phase 3 Registration Trial ...
CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; ...
Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update.
Kiara Taylor has worked as a financial analyst for more than a decade. Her career has involved a number of financial firms, including Fifth Third Bank, JPMorgan, and Citibank. She has filled a number ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results